Cargando…
Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure–response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis polyneuropathy (hATTR-PN). Inotersen PK and TTR level (PD) d...
Autores principales: | Yu, Rosie Z., Collins, Jon W., Hall, Shannon, Ackermann, Elizabeth J., Geary, Richard S., Monia, Brett P., Henry, Scott P., Wang, Yanfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249474/ https://www.ncbi.nlm.nih.gov/pubmed/32286934 http://dx.doi.org/10.1089/nat.2019.0822 |
Ejemplares similares
-
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019) -
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020) -
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019) -
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019) -
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)